secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2022-10-27T23:59:59+00:00
Accession:  0000882095-22-000022
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance
-------------------------------------------------------------

- Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.
- GAAP diluted EPS $1.42 (vs $2.05); Non-GAAP EPS $1.90 (vs $2.65).
- Biktarvy sales +22% to $2.8B; oncology sales +79% to $578M; Veklury -52% to $925M.
- Raises 2022 guidance: product sales $25.9-$26.2B, Non-GAAP EPS $6.95-$7.15.
- Acquired IPR&D $448M, including $389M for MiroBio; operating CF $2.9B in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/0000882095-22-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/gild-20221027.htm
  HTML page:      https://secwatch.observer/filing/0000882095-22-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer